New Stock News | Geneshare Medicines submitted documents to the Hong Kong Stock Exchange, focusing on innovative and effective treatment solutions in the fields of oncology and autoimmunity.

According to the disclosure by the Hong Kong Stock Exchange on December 27, Jinfan Pharmaceutical Technology (Shanghai) Co., Ltd. (referred to as Jinfan Medicine) has submitted a listing application to the Hong Kong Stock Exchange main board, with CITIC SEC as the exclusive sponsor. The prospectus shows that Jinfan Medicine was established in 2017 and is a bio-pharmaceutical company in the commercialization stage, focusing on innovative and effective treatment solutions in the fields of oncology, autoimmunity, and inflammatory diseases. As of the last practical date, the company has established a continuously updated product pipeline, including eight candidate drugs, with five of them being in clinical development stage. The company has two core products - GFH925 and GFH312. GFH925 (fulzerasib, marketed as Dabotert) is an innovative drug discovered by the company, which has received commercial approval in China for the treatment of advanced non-small cell lung cancer (NSCLC), being the first in China and the third globally approved selective Kirsten rat sarcoma (KRAS) G12C inhibitor. GFH312 is an efficient small molecule inhibitor developed by the company, targeting receptor interacting protein kinase 1 (RIPK1) and inhibiting its kinase activity. Jinfan Medicine has obtained FDA approval for an IND to conduct phase 2 clinical trials in the US to evaluate the safety and efficacy of GFH312 in patients with peripheral arterial disease (PAD) with intermittent claudication (IC). In addition to the company's core products, the company is building a comprehensive and differentiated RAS product matrix, including GFH375, an orally bioavailable KRAS G12D small molecule inhibitor. In addition to the innovative RAS matrix, Jinfan Medicine is also committed to further enriching the company's product pipeline, such as GFS202A, a company-developed dual-specific antibody targeting GDF15 and IL-6. The diversified product pipeline is a natural output of the company's validated comprehensive research and development platform, which covers target discovery, molecular discovery and evaluation, translational science, and global clinical development, complemented by the company's professional expertise in key chemistry, manufacturing, and control (CMC) aspects including formulation research and quality analysis. In terms of finances, for the fiscal year 2022 and 2023, Jinfan Medicine's revenues are approximately RMB 105 million and RMB 73.734 million respectively. For the fiscal years 2022, 2023, and the six months ending June 30 of 2023 and 2024, the company incurred losses of approximately RMB 275 million, RMB 508 million, RMB 214 million, and RMB 449 million respectively.